

Leslie A Crews

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7517827/publications.pdf>

Version: 2024-02-01

93
papers

10,091
citations

38660

50
h-index

64668

79
g-index

98
all docs

98
docs citations

98
times ranked

13288
citing authors

#	ARTICLE	IF	CITATIONS
1	Inflammation-driven deaminase deregulation fuels human pre-leukemia stem cell evolution. <i>Cell Reports</i> , 2021, 34, 108670.	2.9	22
2	Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. <i>Cell Stem Cell</i> , 2021, 28, 623-636.e9.	5.2	29
3	Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells. <i>STAR Protocols</i> , 2021, 2, 100565.	0.5	3
4	Deregulation of Splicing in Pediatric Acute Myeloid Stem and Progenitor Cells. <i>Blood</i> , 2021, 138, 2227-2227.	0.6	0
5	ADAR1 Splicing Modulation As a Mechanism to Eradicate Immunologically Silent Leukemia Stem Cells. <i>Blood</i> , 2021, 138, 3321-3321.	0.6	0
6	Selective Targeting of Alternative Splicing Deregulation in Pediatric Acute Myeloid Stem and Progenitor Cells. <i>Blood</i> , 2020, 136, 8-8.	0.6	1
7	Inflammatory Cytokine Responsive Enzymatic Mutagenesis Fuels Myeloproliferative Neoplasm Pre-Leukemia Stem Cell Evolution. <i>Blood</i> , 2019, 134, 3780-3780.	0.6	0
8	Comparative Inflammasome Analysis of Bone Marrow Stroma in Aging and Myelofibrosis. <i>Blood</i> , 2018, 132, 4331-4331.	0.6	1
9	Genetic Modulation of Adenosine-to-Inosine RNA Editing Selectively Disrupts Inflammasome and Extracellular Matrix Genes in Multiple Myeloma. <i>Blood</i> , 2018, 132, 1324-1324.	0.6	0
10	RNA editing-dependent epitranscriptome diversity in cancer stem cells. <i>Nature Reviews Cancer</i> , 2017, 17, 381-392.	12.8	86
11	Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma. <i>Nature Communications</i> , 2017, 8, 1922.	5.8	89
12	RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML. <i>Cell Stem Cell</i> , 2016, 19, 599-612.	5.2	97
13	ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis. <i>Cell Stem Cell</i> , 2016, 19, 177-191.	5.2	182
14	Decoding the RNA Editome of Normal Versus Malignant Progenitor Cell Aging Short Title: RNA Editing in Normal Aging and MDS/AML Stem Cells. <i>Blood</i> , 2016, 128, 1519-1519.	0.6	1
15	Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche. <i>Oncotarget</i> , 2016, 7, 56013-56029.	0.8	34
16	Mechanisms of HIV-1 Tat Neurotoxicity via CDK5 Translocation and Hyper-Activation: Role in HIV-Associated Neurocognitive Disorders. <i>Current HIV Research</i> , 2015, 13, 43-54.	0.2	48
17	An RNA editing fingerprint of cancer stem cell reprogramming. <i>Journal of Translational Medicine</i> , 2015, 13, 52.	1.8	46
18	Targeting Cancer Stem Cell Survival in Plasma Cell Leukemia with a Pan-BCL2 Inhibitor. <i>Blood</i> , 2015, 126, 5351-5351.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Inflammatory Cytokine-Responsive ADAR1 Impairs Let-7 Biogenesis and Promotes Leukemia Stem Cell Generation. <i>Blood</i> , 2015, 126, 4014-4014.	0.6	0
20	RNA Splicing Modulation Impairs Acute Myeloid Leukemia Stem Cell Maintenance. <i>Blood</i> , 2015, 126, 567-567.	0.6	1
21	Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications. <i>Acta Ophthalmologica</i> , 2014, 92, 161-166.	0.6	280
22	Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders. <i>British Journal of Pharmacology</i> , 2014, 171, 5757-5773.	2.7	29
23	Tracking Human Myeloma Cell Therapeutic Resistance Using a Novel Diagnostic Assay for Detection of RNA Editing Biomarkers of Cancer Stem Cell Generation. <i>Blood</i> , 2014, 124, 3406-3406.	0.6	0
24	Regulation of Self-Renewal through Modulation of Let-7 Stem Cell Regulatory Family of microRNAs in Chronic Myeloid Leukemia Stem Cells. <i>Blood</i> , 2014, 124, 4527-4527.	0.6	0
25	Selective elimination of leukemia stem cells: Hitting a moving target. <i>Cancer Letters</i> , 2013, 338, 15-22.	3.2	59
26	ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 1041-1046.	3.3	148
27	Molecular Evolution of Leukemia Stem Cells. , 2013, , 449-458.		1
28	A Highly Selective SF3B1-Targeted Splicing Inhibitor Reduces Human CD34+ Cell Survival and Self-Renewal In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 1653-1653.	0.6	2
29	Inhibition Of Inflammation Driven Leukemia Stem Cell Self-Renewal With a Selective JAK2 Antagonist. <i>Blood</i> , 2013, 122, 1481-1481.	0.6	0
30	Alpha-Synuclein and Neurodegeneration. , 2012, , 303-305.		1
31	Clinical Utility of Objective Tests for Dry Eye Disease. <i>Cornea</i> , 2012, 31, 1000-1008.	0.9	170
32	Distribution of Aqueous-Deficient and Evaporative Dry Eye in a Clinic-Based Patient Cohort. <i>Cornea</i> , 2012, 31, 472-478.	0.9	410
33	Î±-Synuclein Induces Alterations in Adult Neurogenesis in Parkinson Disease Models via p53-mediated Repression of Notch1. <i>Journal of Biological Chemistry</i> , 2012, 287, 31691-31702.	1.6	64
34	NOTCH1 Signaling Promotes Human T-Cell Acute Lymphoblastic Leukemia Initiating Cell Regeneration in Supportive Niches. <i>PLoS ONE</i> , 2012, 7, e39725.	1.1	31
35	Chronic Myeloid Leukemia Stem Cell Biology. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 125-132.	1.2	40
36	Role of Î±-Synuclein penetration into the membrane in the mechanisms of oligomer pore formation. <i>FEBS Journal</i> , 2012, 279, 1000-1013.	2.2	146

#	ARTICLE	IF	CITATIONS
37	Abstract 5217: RNA editing enzyme ADAR1 drives leukemia stem cell differentiation and self-renewal in chronic myeloid leukemia. , 2012, , .		0
38	Abstract 1011: NOTCH1 signaling is essential for leukemia initiating cell self-renewal in T-ALL. , 2012, , .		0
39	Modulation of aberrant CDK5 signaling rescues impaired neurogenesis in models of Alzheimer's disease. Cell Death and Disease, 2011, 2, e120-e120.	2.7	69
40	Increased CDK5 Expression in HIV Encephalitis Contributes to Neurodegeneration via Tau Phosphorylation and Is Reversed with Roscovitine. American Journal of Pathology, 2011, 178, 1646-1661.	1.9	56
41	Regional Comparison of the Neurogenic Effects of CNTF-Derived Peptides and Cerebrolysin in A β 2PP Transgenic Mice. Journal of Alzheimer's Disease, 2011, 27, 743-752.	1.2	19
42	Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease. PLoS ONE, 2011, 6, e19338.	1.1	375
43	Neurotoxic effects of the HCV core protein are mediated by sustained activation of ERK via TLR2 signaling. Journal of NeuroVirology, 2011, 17, 327-340.	1.0	33
44	Phosphorylation of collapsin response mediator protein-2 disrupts neuronal maturation in a model of adult neurogenesis: Implications for neurodegenerative disorders. Molecular Neurodegeneration, 2011, 6, 67.	4.4	29
45	APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis. Brain Structure and Function, 2010, 214, 111-126.	1.2	92
46	Progressive accumulation of amyloid β oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS Journal, 2010, 277, 3051-3067.	2.2	188
47	Selective Molecular Alterations in the Autophagy Pathway in Patients with Lewy Body Disease and in Models of α -Synucleinopathy. PLoS ONE, 2010, 5, e9313.	1.1	327
48	Molecular mechanisms of neurodegeneration in Alzheimer's disease. Human Molecular Genetics, 2010, 19, R12-R20.	1.4	561
49	Increased BMP6 Levels in the Brains of Alzheimer's Disease Patients and APP Transgenic Mice Are Accompanied by Impaired Neurogenesis. Journal of Neuroscience, 2010, 30, 12252-12262.	1.7	189
50	Neuropeptide Y Fragments Derived from Neprilysin Processing Are Neuroprotective in a Transgenic Model of Alzheimer's Disease. Journal of Neuroscience, 2009, 29, 1115-1125.	1.7	75
51	Molecular Pathology of Neuro-AIDS (CNS-HIV). International Journal of Molecular Sciences, 2009, 10, 1045-1063.	1.8	67
52	Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin. Acta Neuropathologica, 2009, 117, 699-712.	3.9	39
53	Role of Synucleins in Alzheimer's Disease. Neurotoxicity Research, 2009, 16, 306-317.	1.3	73
54	Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson's disease by disturbing calcium flux. Journal of Neurochemistry, 2009, 108, 1561-1574.	2.1	139

#	ARTICLE	IF	CITATIONS
55	Inclusion formation and neuronal cell death through neuron-to-neuron transmission of $\hat{\pm}$ -synuclein. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13010-13015.	3.3	1,308
56	Role of $\hat{\pm}$ Degrading Enzymes in Synaptic Plasticity and Neurogenesis in Alzheimer's Disease. , 2009, , 3-12.		0
57	Neurotrophic effects of Cerebrolysin in the Mecp2308/Y transgenic model of Rett syndrome. Acta Neuropathologica, 2008, 116, 425-437.	3.9	17
58	Neuronal injury in simian immunodeficiency virus and other animal models of neuroAIDS. Journal of NeuroVirology, 2008, 14, 327-339.	1.0	27
59	Statins reduce neuronal $\hat{\pm}$ -synuclein aggregation in <i>in vitro</i> models of Parkinson's disease. Journal of Neurochemistry, 2008, 105, 1656-1667.	2.1	147
60	Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice. BMC Neuroscience, 2008, 9, 109.	0.8	74
61	$\hat{\pm}$ -Synuclein Alters Notch-1 Expression and Neurogenesis in Mouse Embryonic Stem Cells and in the Hippocampus of Transgenic Mice. Journal of Neuroscience, 2008, 28, 4250-4260.	1.7	127
62	Biological Transgenic Mouse Models of Alzheimer's Disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 291-301.	1.0	2
63	$\hat{\pm}$ -Synuclein Aggregates Interfere with Parkin Solubility and Distribution. Journal of Biological Chemistry, 2008, 283, 6979-6987.	1.6	54
64	Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's Diseases. PLoS ONE, 2008, 3, e3135.	1.1	233
65	Pathogenesis of Hepatitis C Virus Coinfection in the Brains of Patients Infected with HIV. Journal of Infectious Diseases, 2007, 196, 361-370.	1.9	125
66	Climbing the Scaffolds of Parkinson's Disease Pathogenesis. Neuron, 2007, 53, 469-470.	3.8	9
67	Escalating dose-multiple binge methamphetamine exposure results in degeneration of the neocortex and limbic system in the rat. Experimental Neurology, 2007, 207, 42-51.	2.0	75
68	Neuroprotective Effects of Regulators of the Glycogen Synthase Kinase-3 $\hat{\pm}$ Signaling Pathway in a Transgenic Model of Alzheimer's Disease Are Associated with Reduced Amyloid Precursor Protein Phosphorylation. Journal of Neuroscience, 2007, 27, 1981-1991.	1.7	265
69	Novel strategies for Alzheimer's disease treatment. Expert Opinion on Biological Therapy, 2007, 7, 1853-1867.	1.4	26
70	Dynamics of $\hat{\pm}$ -synuclein aggregation and inhibition of pore-like oligomer development by $\hat{\pm}$ -synuclein. FEBS Journal, 2007, 274, 1862-1877.	2.2	149
71	Transgenic animal models of neurodegenerative diseases and their application to treatment development. Advanced Drug Delivery Reviews, 2007, 59, 1093-1102.	6.6	77
72	Toll-like receptor pathway gene expression is associated with human immunodeficiency virus-associated neurodegeneration. Journal of NeuroVirology, 2007, 13, 496-503.	1.0	27

#	ARTICLE	IF	CITATIONS
73	Effects of Cerebrolysin [®] on neurogenesis in an APP transgenic model of Alzheimer's disease. <i>Acta Neuropathologica</i> , 2007, 113, 265-275.	3.9	109
74	Deficiency in neuronal TGF- β 2 signaling promotes neurodegeneration and Alzheimer's pathology. <i>Journal of Clinical Investigation</i> , 2006, 116, 3060-3069.	3.9	302
75	Astroglial Activation of Extracellular-Regulated Kinase in Early Stages of Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 142-151.	0.9	77
76	Genetically Engineered Mouse Models of Neurodegenerative Disorders. , 2006, , 371-408.		0
77	Synaptic remodeling during aging and in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2006, 9, 91-99.	1.2	111
78	Cerebrolysin decreases amyloid- β 2 production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. <i>Journal of Neuroscience Research</i> , 2006, 83, 1252-1261.	1.3	98
79	Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users. <i>Neurology</i> , 2006, 67, 1486-1489.	1.5	95
80	Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. <i>Nature Neuroscience</i> , 2005, 8, 1343-1349.	7.1	385
81	Corrigendum to "Patterns of gene dysregulation in the frontal cortex of patients with HIV encephalitis". <i>Journal of Neuroimmunology</i> , 2005, 162, 197.	1.1	0
82	Lysosomal pathology associated with α -synuclein accumulation in transgenic models using an eGFP fusion protein. <i>Journal of Neuroscience Research</i> , 2005, 80, 247-259.	1.3	77
83	Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound Cerebrolysin?. <i>Journal of Neural Transmission</i> , 2005, 112, 269-282.	1.4	50
84	Neurological and Neurodegenerative Alterations in a Transgenic Mouse Model Expressing Human α -Synuclein under Oligodendrocyte Promoter: Implications for Multiple System Atrophy. <i>Journal of Neuroscience</i> , 2005, 25, 10689-10699.	1.7	217
85	High β -Secretase Activity Elicits Neurodegeneration in Transgenic Mice Despite Reductions in Amyloid- β 2 Levels. <i>Journal of Biological Chemistry</i> , 2005, 280, 32957-32967.	1.6	89
86	Effects of α -Synuclein Immunization in a Mouse Model of Parkinson's Disease. <i>Neuron</i> , 2005, 46, 857-868.	3.8	533
87	β -Synuclein Regulates Akt Activity in Neuronal Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 23622-23629.	1.6	93
88	An antiaggregation gene therapy strategy for Lewy body disease utilizing β -synuclein lentivirus in a transgenic model. <i>Gene Therapy</i> , 2004, 11, 1713-1723.	2.3	95
89	Patterns of gene dysregulation in the frontal cortex of patients with HIV encephalitis. <i>Journal of Neuroimmunology</i> , 2004, 157, 163-175.	1.1	94
90	The role of mitochondrial alterations in the combined toxic effects of human immunodeficiency virus Tat protein and methamphetamine on calbindin positive-neurons. <i>Journal of NeuroVirology</i> , 2004, 10, 327-337.	1.0	57

#	ARTICLE	IF	CITATIONS
91	The Role of α -Synuclein Assembly and Metabolism in the Pathogenesis of Lewy Body Disease. <i>Journal of Molecular Neuroscience</i> , 2004, 24, 343-352.	1.1	45
92	Insights into the Pathogenesis of Hydrocephalus from Transgenic and Experimental Animal Models. <i>Brain Pathology</i> , 2004, 14, 312-316.	2.1	58
93	Role of Protein Aggregation in Mitochondrial Dysfunction and Neurodegeneration in Alzheimer's and Parkinson's Diseases. <i>NeuroMolecular Medicine</i> , 2003, 4, 21-36.	1.8	410